Brentwood, United States
DayTwo, founded in 2015 and headquartered in the United States, is at the forefront of personalized nutrition, leveraging advanced microbiome analysis to address metabolic diseases. With a focus on health care, health and wellness, and nutrition, the company is making strides in precision health through proprietary algorithms and state-of-the-art sequencing methods.
DayTwo stands out due to its largest high-resolution sequenced data set, encompassing over 90,000 samples. The organization translates intricate microbiome data into actionable dietary recommendations, underpinned by extensive research published in top-tier journals like Nature and Cell.
Backed by a notable £26.30M Series B investment on 31 May 2021, major investors including Cathay Innovation, 10D, and aMoon demonstrate significant confidence in its growth trajectory. DayTwo's personalized approach to nutrition positions it as a pivotal player in the burgeoning field of personalized health solutions.
